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I should think that, like me, there are several 
other people of my generation who will fi nd it dif-
fi cult in the future to justify a visit to the pharmacy 
every three months. A prescription, information 
about a drug and checking a reimbursement enti-
tlement by the Social Insurance Institution are not 
suffi cient grounds. Starting a new drug treatment 
and receiving the associated information are natu-
ral causes for a visit, but while the drug treatment 
continues I would appreciate even other alternatives. 
I think I would be content with an annual medical 
examination and having the support of a pharmacist 
specializing in drug information. I am not denying 
that there would still be a great number of patients 
in Finland who would continue to value their visits 
to the pharmacy very highly indeed.
Pharmacy operations ought to develop with a 
focus on the new conditions under which they oper-
ate, the changing environment and the patients’ new 
expectations. Electronic prescriptions create the fa-
cilities for the electronic pharmacy services described 
above. This new way of providing pharmacy services 
requires a transfer of the pharmacy operations to the 
electronic environment and the development of new 
models of logistic operations. As a business model 
this bears resemblances to the rest of e-commerce. 
In pharmacy operations the most relevant difference 
is of course the requirement for drug information. 
Direct drug information from the pharmacist to the 
patient is naturally the most effi cient type, but situ-
ations exist where the new lines of action evidently 
achieve an adequate and acceptable level of service 
from the patient’s point of view.
The pharmacy working group set up by the 
Ministry of Social Affairs and Health in Finland has 
discussed the position and the development of the 
pharmacy institution. Electronic pharmacy services 
are a totally new service option, the development of 
which still requires a solution to the question of how 
the logistic part of the electronic pharmacy services 
could be appropriately arranged in the professional 
pharmacy system.
Electronic prescriptions introduce signifi cant im-
provements in the controlling of drug treatment. In 
the new system, the prescription is prepared electron-
ically and thereafter transferred via data networks to 
the prescription centre. The pharmacy has the task of 
supplying the patient with the prescribed medicine in 
accordance with the information received from the 
prescription centre, and is responsible for the drug in-
formation associated with supplying it to the patient.
The use of electronic prescriptions makes it pos-
sible to review the patient’s entire medication already 
at the stage of prescribing and thereby to better the 
quality of drug treatment. It improves the evaluation 
of the drug treatment of the patient and avoids any 
drug interactions. The changeover diminishes un-
necessary work at the pharmacy. The pharmacy no 
longer needs to rewrite the instructions already once 
written by the doctor. Hand-written prescriptions 
continue in the 21st century to cause misinterpreta-
tions at pharmacies. These prescriptions are also doc-
uments which are very easy to forge. The importance 
to the patients of the changeover lies in the fact that 
they no longer need to walk to the pharmacy with a 
prescription in their hand. The system also gives the 
patient a choice to choose, since the prescription may 
be collected from any pharmacy.  It is also easier for 
the patient to check the validity of the prescriptions 
and the quantity of unsupplied drugs.
It rings a bell – it is a familiar development. As 
late as in the 1980’s I was still physically taking 
my green deposit book to the bank for the credit 
and debit to be recorded. Then the banking busi-
ness changed form and we entered the electronic era 
which in the 21st century has developed into the 
modern electronic banking system. Money transac-
tions are still made on my bank account, and I am 
regularly keeping an eye on the situation and making 
payment orders. I have my own personal contact at 
my bank, and the contact person is available should 
problems arise or should I want to discuss my fi nan-
cial concerns. The last time I remember having visited 
a bank was when signing documents for a house 
mortgage. 
Jussi Holmalahti
Professor, Head of the Enforcement and Inspection Department
National Agency for Medicines
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Medicines education became part of the comprehensive school health education curriculum along with 
the reformed basis of the curricula in Finland in 2004 (1). Teachers are nevertheless unfamiliar with the 
subject and it is not clearly deﬁ ned in the foundations of the curricula. Medicines education is mentioned 
in the primary school discipline known as nature and environmental education for year-classes 1–4 as 
follows: ‘the pupil should be familiar with the basic rules governing the use of medicines’, and in the health 
education discipline of the secondary school it says: ‘the pupil should be familiar with the basics of the 
appropriate use of medicines’. It is clear that teachers should be given the means to carry out medicines 
education and teach it in practice.
A joint effort in medicines education 
Katri Hämeen-Anttila
Ph. D. (Pharm.)
Department of Social Pharmacy
University of Kuopio
In order to assist teachers in their 
work, an appropriate website for 
medicines education in compre-
hensive schools was set up in the 
Department of Social Pharmacy at 
the University of Kuopio in Fin-
land (www.uku.fi /laakekasvatus 
partly in English). The web pages 
were designed as part of my dis-
sertation, as a project for Mas-
ter of Pharmacy students (2). Five 
comprehensive school teachers 
participated as experts. 
The website about medicines 
education contains plenty of 
independent current information 
about the use of medicines. As an 
aid in the planning of the teach-
ing and based on research results 
we have set out plans for lessons 
to be given at various class levels 
(3). To facilitate the practical 
introduction of teaching we also 
prepared complete ready-to-use 
teaching lesson plans. During my 
study, 14 comprehensive school 
teachers tested the usability of 
the fi rst version of the medicines 
education pages. Based on their 
critical comments the web pages 
were redesigned and provided 
with a completely new image (4). 
The present medicines education 
website is updated twice a year.
In order to render the medi-
cines education more concrete 
we defi ned its aims as follows: to 
teach children to become sensi-
ble users of medicines, to make 
children prepared to talk with a 
doctor and at the pharmacy about 
issues involving the use of their 
own medication and to under-
stand the purpose of medicines in 
the treatment of diseases and as 
prophylactic measures. The aim is 
also to promote critical and evalu-
ative thinking. Children should 
learn to search for information 
about medicines and assess the 
reliability of the information they 
have found. This is especially im-
portant in the era of the Internet.
The underlying current in the 
medicines education pages is the 
ideology of empowerment (5-7). 
Consistently with this, the fun-
damental principle of learning is 
the individual’s own experience, 
and it is especially important that 
the learner is an active participant 
and not a passive recipient of 
information or an outside ob-
server (6, 8). From the point of 
view of the ideology of empower-
ment the above-mentioned aims 
of medicines education appear, for 
example, as follows: 
   as required by their individual 
stage of development children 
are taught about the correct 
use of medicines beginning as 
early as in the primary school; 
issues are discussed for ex-
ample about what is good to 
know about medicines before 
starting to use them – just 
warning about medicines is 
not enough, 
    skills associated with the use 
of medicines are practiced, 
for example by assessing the 
prevalence of adverse reac-
tions described in the package 
leafl et or by refl ecting on how 
to avoid them, 
    pupils are encouraged to carry 
out active conversations about 
medicines with health care 
professionals, which may for 
example be practiced through 
role-playing during medicines 
education lessons involving a 
visit to the pharmacy.
On the website, with the help 
of scheduled lessons, medicines 
education is structured as an 
entity with a logical progression. 
The subjects to be taught are 
designed in such a way that they 
support the targets of medicines 
education as set out in the cur-
riculum. The entities taught to 
7th–9th graders (in accordance with 
the school system in Finland) are 
more extensive and provide more 
in-depth information than those 
taught to 3rd–6th graders. In the 
lower secondary school an addi-
tional viewpoint is also offered by 
the search for information about 
medicines and by assessment of its 
reliability. The aim of medicines 
education targeted at 1st–2nd grad-
ers is to establish a base for the 
understanding of the correct use 
of medicines.
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The fundamental principles of 
the curricula require teachers to 
discuss the correct use of medi-
cines at their lessons (1). The fu-
ture will show what sort of recep-
tion this challenge receives among 
them and how they will use the 
website of medicines education in 
their teaching. The biggest obsta-
cle in putting medicines education 
into practice may actually be the 
teachers’ own attitudes towards 
the use of medicines (9). 
Medicines education is not 
the responsibility of teachers 
alone. The biggest responsibil-
ity for teaching the correct use 
of medicines lies of course with 
the parents. The parents’ own 
attitudes are also apparent in 
their actions. Viewpoints strongly 
against medicines lead to a situa-
tion where parents themselves do 
not wish to use medicines or give 
them to their child, nor do they 
wish to discuss them (10-12). To 
warn the child about medicines 
may also develop in the child a 
very reserved attitude towards 
them (13). It is nevertheless by 
personal experiences and by our 
own active conduct that we could 
promote the process of empower-
ment (6, 8). It is a very different 
experience that the child gets of 
the use of medicines when the 
mother gives her child a tablet 
and tells the child to only take 
one, compared with the situation 
where the mother explains why 
the medicine should be taken and 
perhaps reads the package leafl et 
together with the child before giv-
ing the medicine. Parents can also 
encourage their child to discuss 
medicines when meeting a health 
care professional.
A child learns about medi-
cines, their use and the way in 
which they are discussed when, 
for example, attending a doctor’s 
appointment, or visiting a school 
nurse, a pharmacy or a dentist. 
A health care professional may, 
however, fi nd it diffi cult to talk 
about the child’s disease and its 
treatment directly with the child 
at the child’s level of development 
(14-18). We therefore need to 
be educated about the cognitive 
development of children and its 
effects on communication. 
The use of medicines is dis-
cussed in school at a general level 
and various issues associated with 
the correct use are deliberated 
over. The child’s disease and medi-
cation are discussed specifi cally 
with a health care professional. 
The parents on their part in their 
everyday life give their child a 
model of how to use medicines, 
a model which the child will use 
when becoming independent (19- 
20). It is a question of collabora-
tion between a number of parties, 
which in its entirety is visible to 
the child alone. Each party should 
refl ect on the form of its own con-
tribution to the child’s education 
and the way in which it conducts 
a conversation with the child 
about medicines and their uses.
If medicines education be-
comes a part of the health educa-
tion in schools, children will grow 
into becoming a more know-
ledgeable generation of medicine 
users. They learn to become active 
participants in discussions, who 
know what issues are involved in 
the correct use of medicines. We 
are still a long way away from 
changing the strong perceptions 
of laymen, and we need the input 
of all parties. While attempting 
to achieve this, it should be borne 
in mind that medicines education 
is not a question where children 
would be encouraged to use more 
medicines or use them independ-
ently and at an ever younger age. 
Medicines education is about par-
ticipation in one’s own pharma-
cotherapy, about asking questions 
and discussing and about the 
gradual and well-planned trans-
fer of responsibilities to children 
while they are growing into be-
coming future users of medicines.
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Learning from medication errors
An overdose of methotrexate in a hospital patient
Why did a typical error of medication take place in our hospital?
In September 2006, an 86-year-
old woman arrived at the hos-
pital on referral owing to dysp-
noea. She was found clinically 
and on MRI to suffer from pul-
monary embolism. She was ad-
mitted to the hospital for treat-
ment and medication was started. 
Among the eight medicines which, 
according to the referral, were to 
be taken at home there was an 
ongoing anti-rheumatic medica-
tion of ‘Trexan 5 mg on Tuesdays 
(in Finnish tiistaisin)’ which the 
audio typist had interpreted as 
‘Trexan 5 mg in the evening (in 
Finnish iltaisin)’. The medication 
was recorded in this format in the 
ward medication list.
The patient initially recov-
ered well from the pulmonary 
embolism, but over a week after 
admission to hospital she com-
plained about a sore mouth and 
her general condition became 
worse. Infection was suspected, 
but instead anaemia and neu-
tropaenia were detected. This 
fi nding gave an incentive 12 days 
after admission for reviewing the 
patient’s medication, and it was 
subsequently detected that meth-
otrexate had been given at a dose 
of 5 mg every day whereas the 
administered dose should have 
been 5 mg once a week. 
Despite efforts to treat the 
patient, she did not recover from 
the neutropaenia, but died of 
sepsis after 20 days of hospital 
treatment. Autopsy showed signs 
of bone marrow depression and, 
in addition, pneumonia. The 
microscopic studies are not yet 
completed, but an overdose of 
methotrexate appears to be the 
likely cause of death.
Analysis of the case
Except for rare instances, medi-
cines are administered daily. The 
once a week administration of 
methotrexate has consequently 
caused numerous medication er-
rors. The number is so high that 
we are well aware of the risk even 
at our hospital. We are neverthe-
less faced here with the classic 
‘Swiss cheese phenomenon’, very 
familiar to quality system experts. 
When the holes in the slice of 
cheese land on the same spot af-
ter an adequate number of slices, 
the quality default ‘cuts through 
the whole cheese’ and an accident 
is unavoidable. Within our hospi-
tal the course of events can be an-
alysed as follows, with the aid of 
fi ve ‘cheese slices’:
1. Our doctor on duty acted 
very professionally by diagnos-
ing a life threatening pulmo-
nary embolism and introducing 
immediate appropriate treat-
ment. Among other duties he 
probably dictated ‘Trexan 5 mg 
on Tuesdays (tiistaisin)’, but an 
audio typist at her word proces-
sor, tired while performing an 
evening duty, wrote ‘Trexan 
5 mg in the evening (iltaisin)’. 
Due to the fact that our hospital 
emergency room in the evenings 
is always busy, and due to the 
constant complaints about long 
patient ‘turnaround times’, the 
doctor did not check the text he 
had dictated. It was necessary to 
admit the ill elderly patient for 
treatment on the ward with-
out delay. Two processes were 
thereby set in motion, that of 
the treatment of the pulmonary 
embolism and of the medication 
error.
2. It was necessary to admit the 
patient to a ward in which there 
was no experience of methotrex-
ate therapy. The nurse therefore 
recorded the patient’s medica-
tion from the newly produced 
hospital record of internal medi-
cine without noticing anything 
specifi c in the dosage of meth-
otrexate.
3. The following morning the 
ward was actually visited by a 
locum, because the senior doc-
tor was off duty. All the 20 pa-
tients in the ward were unfamil-
iar to the locum, so his visit to 
the ward was long and tiresome. 
He was too exhausted to make 
a thorough enough check of the 
medications of patients admitted 
on the previous evening.
4. The following morning the 
senior ward doctor considered 
the recovery from pulmonary 
embolism to have started well, 
and he had consequently no 
reason to review the patient’s 
medication list.
5. Over a week after admission 
to hospital the patient’s recovery 
stopped, however, and her con-
dition took a downward turn. 
In English
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A ‘safety alert’ about incorrect dosage of methotrexate proposed by the UK’s National 
Patient Safety Agency, NPSA. Methotrexate therapy was denominated as a ‘high risk 
treatment process’ in the UK in 2004 after 25 mortalities had been reported as a conse-
quence of the treatment.
A complicating infection was 
suspected at fi rst, and blood 
tests, for example, were subse-
quently taken. This is when, in 
addition to anaemia, neutropae-
nia was detected and an im-
mediate check of the medicines 
list revealed that methotrexate 
therapy had continued for the 
entire hospitalisation period, i.e. 
for 12 days, at a dose of 5 mg 
every day. Unfortunately, the 
error was detected too late.
What have we learned from this?
Our doctors on duty, who work 
under enormous work pressures, 
have not been required to pro-
duce a handwritten list of medi-
cations or other therapies, or to 
confi rm their case records by their 
signature for all patients admit-
ted to hospital. The lack of this 
requirement may also be defended 
by the fact that the doctor on du-
ty is responsible for the treatment 
of admitted patients only ‘until 
the following morning’, when the 
senior ward doctor will exam-
ine the patient and prescribe the 
treatment. In fact, following this 
procedure there have been no ac-
cidents (as far as we know) for at 
least 5 years. We have now never-
theless altered the procedure. All 
doctors on duty are required to 
check any case reports that they 
dictate.
I would nevertheless like to 
emphasise one point. For decades 
we have enjoyed an excellent 
pharmacotherapy quality system 
in outpatient care: the dispensing 
pharmacist has phoned from the 
pharmacy if there have been any-
thing suspicious about the admin-
istration we have prescribed, es-
pecially in the case of an excessive 
dose. Could this medication error 
have been avoidable if the pre-
scription had been handed out in 
outpatient care? I am fairly sure it 
would have been. The pharmacy 
would at least have contacted 
us, merely because methotrexate 
should not be administered with-
out intermission for longer than 
a maximum of fi ve consecutive 
days. Hospitals should therefore 
also employ pharmacists or other 
quality assessors of the drug treat-
ment given. The electronic data 
systems at our hospital have not 
yet had integrated into them func-
tions that would alert us and give 
an advance warning about incor-
rect doses of medicines (Figure).
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About 0.8% of Finns suffer from 
rheumatoid arthritis (1), while 
about 1.6% of the population are 
entitled to special refunds per-
taining to rheumatic diseases (2). 
In 2004 there were 81,527 peo-
ple in Finland with entitlement 
to a special refund of the cost of 
their medicines for disseminated 
connective tissue diseases, rheu-
matic arthritis and similar con-
ditions (special refund catego-
ry 202). About a third of them 
were men. Of those entitled to re-
funds, 51,907 were reimbursed 
for the cost of their conventional 
antirheumatic agents (3). The av-
erage annual costs of antirheu-
matics amounted to EUR 252 per 
patient (3).
Great progress has been made 
in the medical treatment of rheu-
matoid arthritis in the past couple 
of decades (4-6). Rheumatic 
diseases were previously treated 
with antirheumatics known as 
conventional antirheumatics, such 
as sulphasalazine, hydroxychloro-
quine and corticosteroids (5, 6). 
Methotrexate has since become 
the primary medication for ac-
tive rheumatoid arthritis, both 
alone and in combination with 
other drugs (6, 7). The benefi ts 
of combination treatments have 
been recognised in several studies, 
perhaps resulting consequently in 
an increase in their use (4, 5, 7). 
Nowadays medical treatment of 
rheumatoid arthritis consists of 
antirheumatic and immunosup-
pressive drugs and anti-infl amma-
tory analgesics (5, 7) with varied 
effi cacy depending on the drug 
and on the individual.
The most recently introduced 
antirheumatics include biologi-
cal medicinal products, such as 
etanercept, infl iximab, adalimu-
mab and anakinra (5, 8). Bio-
logical medicinal products for the 
treatment of rheumatic disease 
are very effective, but they are 
extremely expensive, and their use 
is consequently directed towards 
those who will most benefi t from 
the treatment. In 2004 a total of 
1,502 persons received a reim-
bursement from the Social Insur-
ance Institution for the cost of 
the biological medicinal products 
eligible for restricted basic refund 
(category 313). The average cost 
per patient was EUR 12,803, and 
total costs amounted to EUR 19.2 
million, i.e. over one and half 
times as much as when compared 
with the total costs of conven-
tional antirheumatics (EUR 12.6 
million) (3).
The aim of this study was to 
describe the use of conventional 
antirheumatics and corticoster-
oids for the treatment of dissemi-
nated connective tissue diseases, 
rheumatic arthritis and similar 
conditions. The regional and 
socio-economic spread of long-
term use of prescription drugs for 
rheumatic diseases in Finland in 
2004 was also studied. The study 
was carried out as a register-based 
survey of the data of the Social 
Insurance Institution and Statis-
tics Finland. The study subjects 
were randomly chosen among 
patients entitled to reimburse-
ment of medicine costs under the 
special refund category 202. Their 
reimbursed costs of antirheumat-
ics in that refund category were 
included in the data along with 
the total annual costs of their 
other reimbursed medications.
The subjects in the study 
consisted of 29,433 patients suf-
fering from disseminated con-
nective tissue diseases, rheumatic 
arthritis and similar conditions, 
who received a total of 54,544 
prescriptions for their antirheu-
matic agents in 2004. The sub-
jects therefore covered 36% of the 
individuals with special refund 
entitlement 202 and 57% of those 
reimbursed for the cost of their 
conventional antirheumatic agents 
in 2004. The proportion of male 
subjects was 31%.
Results
In comparison with the total pop-
ulation, the prevalence of dissem-
inated connective tissue diseas-
es, rheumatic arthritis and simi-
lar conditions among the subjects 
was on average higher in wom-
en, the elderly, those with a low-
er level of education, in the Finn-
ish-speaking population, small 
town residents and residents out-
side Helsinki and Uusimaa hospi-
tal district, than in men, younger 
patients, those with a higher lev-
el of education, those with moth-
er tongues other than Finnish 
or Swedish, and large town resi-
dents. Division by age and sex of 
Consumption of conventional antirheumatics in 
Finland in 2004
Drug consumption
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Fig. 1. Division by age and sex, and percentage of the corresponding population group.
the subjects is presented in Fig. 1.
The 10 most commonly used 
therapies (62%) are presented 
in the Table, which incorporates 
all corticosteroids including both 
injections and tablets. The drugs 
most commonly used alone in-
cluded sulphasalazine, methotrex-
ate and hydroxychloroquine, and 
the most common combination 
treatments were methotrexate 
with prednisolone or methotrex-
ate with sulphasalazine. Sul-
phasalazine was a distinctly more 
expensive drug compared with 
prednisolone, methotrexate and 
hydroxychloroquine (Table). The 
combination of azathioprine and 
methotrexate was the most com-
monly used in the 0–19-year-old 
age group, sulphasalazine among 
the 20–59-year-olds, and systemic 
corticosteroids in the over 59-
year-olds.
During the year the study sub-
jects were each on average using 
two antirheumatic agents. The 
number of conventional antirheu-
matics and corticosteroids in 
relation to the year of introduc-
tion of the special refund entitle-
ment is presented in Fig. 2. That 
Figure shows that those who had 
recently received their special re-
fund entitlement were on average 
given a multi-medication treat-
ment more often than those who 
had been ill for a longer period of 
time. This refl ects fairly accurately 
the Current Care guidelines which 
suggests that a recently acquired 
rheumatoid arthritis be treated 
by administering a combination 
therapy (7). A total of 15,447 
(52%) of the subjects used sys-
temic corticosteroids, and of these 
443 used more than one cortico-
steroid during the year. The use of 
corticosteroids was more common 
in the long-term sufferers (Fig. 2).
The costs of conventional 
antirheumatics in the data were 
The most commonly used monotherapies and combination treatments using conven-
tional antirheumatics and systemic corticosteroids.
Medication Number  Average   
 of users    cost, €/
       person/year
 1. Systemically used corticosteroids (H02AB) 4,380   49
 2. Sulphasalazine (A07EC01) 3,432 193
 3. Oral methotrexate (L04AX03) 2,266   55
 4. Systemically used corticosteroids and oral methotrexate 1,883   85
 5. Hydroxychloroquine (P01BA02) 1,559   56
 6. Sulphasalazine and systemically used corticosteroids 1,100 237
 7. Sulphasalazine and oral methotrexate   996 260
 8. Systemically used corticosteroids and hydroxychloroquine   996   85
 9. Systemically used corticosteroids, oral methotrexate and 
      hydroxychloroquine   827 151
10. Oral methotrexate and hydroxychloroquine   813 120
In English
51 1.2007 TABU
Fig. 2. The average number of conventional antirheumatics and the proportion of syste-
mic corticosteroid use in relation to the start of special refund entitlement.
about EUR 242 (median of EUR 
119); EUR 264 for men (median 
of EUR 135), and EUR 233 for 
women (median of EUR 111). 
The costs were highest in the age 
group of about 20 to 34-year-olds 
and lowest in the over 75-year-
olds. Overall, the medicine costs 
reimbursed by the Social Insur-
ance Institution in 2004 and 
represented in the data totalled 
EUR 1,364 on average (median 
of EUR 663, range between EUR 
3.36 and EUR 48,291).
Conclusions
A more recently acquired rheuma-
tism was on average treated with 
a greater number of drugs and 
more rarely with systemic cor-
ticosteroids. The most common 
antirheumatics used either alone 
or in combination included sul-
phasalazine, prednisolone, meth-
otrexate and hydroxychloroquine. 
The annual costs of conventional 
antirheumatics were on average 
EUR 242 per person.
Even though the proportion 
of patients using new biological 
medicinal products among those 
suffering from rheumatism was 
only a couple of percentages, 
the costs of biological medicinal 
products already account for a 
major part of the total cost of the 
medicines used in the treatment of 
rheumatism. It would therefore be 
appropriate to study the distribu-
tion of these high costs and excep-
tionally costly treatments among 
the various parts of the country 
and by age and socio-economic 
group.
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Recommendation for quality criteria for sales 
promotions of medicines 
The work of pharmaceutical sales representatives is marketing, which is aimed at promoting the use of medi-
cines. A sales promotion event at its best provides up-to-date and good quality information about medicines 
and their use to practising doctors and pharmacists.
In line with the rest of the pharmaceutical marketing, the National Agency for Medicines (NAM) in Fin-
land also monitors compliance with all parts of the pharmaceutical legislation at sales promotions. NAM 
has established quality criteria for these sales promotion events based on the points in the Medicines Act and 
Decree important with respect to the communication of appropriate information about medicines which pro-
motes their correct and safe use.
The quality criteria comprise a recommendation which NAM hopes that the pharmaceutical companies 
will follow in their marketing. To the professional attending a sales promotion event the recommadation will 
give a perception of what can be expected  of the information content of the presentation. Throughout the 
current year NAM will monitor the extent to which the criteria are followed at these events.
1. A sales promotion representative should have appropriate training (e.g. ‘RLE’ - registered pharmaceu-
tical sales representative). The education should provide basic information which will be suffi cient to 
enable the representative to give information about the medicine which is as comprehensive as possi-
ble.
2. Participants in sales promotion events should be given the current SPC (Summary of Product Charac-
teristics) of the medicinal product. Information about the legal prescription and legal terms of supply 
of the medicine, including details of price and reimbursement, should also be available to the partici-
pants in the event. In addition to unit prices, price comparisons should also address the total costs of 
drug treatment.
3. Information given about the medicinal product should in all its details correspond to the information 
contained in the SPC. Research results used in the sales promotion events which are not included in 
the SPC should correspond with or support the information in the SPC.
4. The focus of the presentation may only be on a therapeutic indication approved for the medicinal 
product. Presentation of the use of the medicine for any other therapeutic indication is prohibited, 
even if it has had proven scientifi c evidence, or another indication has been approved in another coun-
try, or planning of an extension of the indication in the SPC is under way, or an application for an 
extension has been fi led. In addition to the therapeutic indication, the presentation should address any 
other recommendations that exist for the use of the medicine.
5. The source of the information used at the presentation should be given accurately, and any publica-
tions and previously unpublished references should be made available to the participants in the sales 
promotion event.
6. Any quotations, fi gures and tables extracted from the literature or research material should be ac-
curately presented in accordance with the original source. Different research results may not be com-
bined, for example for the purpose of comparison of medicinal products.
7. Adverse reactions, interactions and contraindications and other issues involved in the safe use of the 
medicinal product should be stated with suffi cient clarity.
8. Any material used at the sales promotion event should convey faithfully the medical importance of the 
product as a whole in relation to other treatment options.
9. A sales promotion of medicine is aimed and targeted only at individuals authorised to prescribe and 
dispense the medicinal product.
10. The presentation should focus on information relating to the medicinal product. Any hospitality of-
fered in conjunction with the sales promotion event should be moderate.
          Tiina Kostiainen
